Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
strategic review
Biotech
Keros culls phase 2 PAH program, 70 staff roles
Keros is discontinuing development of its investigational TGF-β inhibitor in PAH after the asset missed the mark in both efficacy and safety.
Gabrielle Masson
May 29, 2025 10:10am
Leap halves head count amid 'difficult market environment'
May 13, 2025 9:10am
Charles River launches strategic review, shakes up board
May 7, 2025 11:14am
Pliant cuts workforce by 45% after bexotegrast trial safety woes
May 2, 2025 7:33am
George Church spinout restructures, considers strategic options
Mar 13, 2025 2:00pm
US biotech finds Relief via reverse merger
Nov 4, 2024 1:05pm
